Activation of executioner caspases is a predictor of progression-free survival in glioblastoma patients: A systems medicine approach

Cell Death and Disease

Volumn 4, Issue 5, 2013, Pages

  Murphy, A C ^a   Weyhenmeyer, B ^a   Schmid, J ^a   Kilbride, S M ^a   Rehm, M ^a   Huber, H J ^a   Senft, C ^b   Weissenberger, J ^b   Seifert, V ^b   Dunst, M ^c   Mittelbronn, M ^a   Kogel D ^b   Prehn, J H M ^a   Murphy, B M ^a  

^a Centre for Systems Medicine   (Ireland)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Apoptosis; Glioblastoma; Systems medicine

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE; PROCASPASE 3; PROCASPASE 9; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TEMOZOLOMIDE; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; AGED; APOPTO CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELL DEATH; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MATHEMATICAL MODEL; MULTIMODALITY CANCER THERAPY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SURVIVAL RATE; SYSTEMS BIOLOGY; TREATMENT RESPONSE; TUMOR CELL;

ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; BRAIN NEOPLASMS; CASPASE 3; CASPASE 9; CASPASES; CELL SURVIVAL; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MITOCHONDRIAL PROTEINS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84879380921     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.157     Document Type: Article

References (43)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
2. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001; 15: 1311-1333.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
4. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
5. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005; 64: 479-489.
6. Krakstad C, Chekenya M. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer 2010; 9: 135.
7. Ziegler DS, Kung AL, Kieran MW. Anti-apoptosis mechanisms in malignant gliomas. J Clin Oncol 2008; 26: 493-500.
8. Stegh AH, Kim H, Bachoo RM, Forloney KL, Zhang J, Schulze H et al. Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev 2007; 21: 98-111.
9. Ruano Y, Mollejo M, Camacho FI, Rodriguez de Lope A, Fiano C, Ribalta T et al. Identification of survival-related genes of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma multiforme. Cancer 2008; 112: 1575-1584.
10. Strasser A, Cory S, Adams JM. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J 2011; 30: 3667-3683.
11. Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003; 22: 7414-7430.
12. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997; 90: 405-413.
13. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479-489.
14. Hu Y, Benedict MA, Ding L, Nunez G. Role of cytochrome c and dATP/ATP hydrolysis in Apaf-1-mediated caspase-9 activation and apoptosis. EMBO J 1999; 18: 3586-3595.
15. Zou H, Li Y, Liu X, Wang X. An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999; 274: 11549-11556.
16. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102: 33-42.
17. Chai J, Du C, Wu JW, Kyin S, Wang X, Shi Y. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 2000; 406: 855-862.
18. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2,-3,-6,-7,-8, and-10 in a caspase-9-dependent manner. J Cell Biol 1999; 144: 281-292.
19. Janicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998; 273: 9357-9360.
20. Bodey B, Bodey V, Siegel SE, Nasir A, Coppola D, Hakam A et al. Immunocytochemical detection of members of the caspase cascade of apoptosis in high-grade astrocytomas. In Vivo 2004; 18: 593-602.
21. Wagenknecht B, Glaser T, Naumann U, Kugler S, Isenmann S, Bahr M et al. Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma. Cell Death Differ 1999; 6: 370-376.
22. Rehm M, Huber HJ, Dussmann H, Prehn JH. Systems analysis of effector caspase activation and its control by X-linked inhibitor of apoptosis protein. EMBO J 2006; 25: 4338-4349.
23. Huber HJ, Rehm M, Plchut M, Dussmann H, Prehn JH. APOPTO-CELL-a simulation tool and interactive database for analyzing cellular susceptibility to apoptosis. Bioinformatics 2007; 23: 648-650.
24. Hetschko H, Voss V, Horn S, Seifert V, Prehn JH, Kogel D. Pharmacological inhibition of Bcl-2 family members reactivates TRAIL-induced apoptosis in malignant glioma. J Neurooncol 2008; 86: 265-272.
25. Hammond LA, Eckardt JR, Kuhn JG, Gerson SL, Johnson T, Smith L et al. A randomized phase I and pharmacological trial of sequences of 1, 3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. Clin Cancer Res 2004; 10: 1645-1656.
26. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
27. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009; 27: 5743-5750.
28. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350-1354.
29. Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 2007; 26: 186-197.
30. Johnson CE, Huang YY, Parrish AB, Smith MI, Vaughn AE, Zhang Q et al. Differential Apaf-1 levels allow cytochrome c to induce apoptosis in brain tumors but not in normal neural tissues. Proc Natl Acad SciUSA 2007; 104: 20820-20825.
31. Watanabe T, Hirota Y, Arakawa Y, Fujisawa H, Tachibana O, Hasegawa M et al. Frequent LOH at chromosome 12q22-23 and Apaf-1 inactivation in glioblastoma. Brain Pathol 2003; 13: 431-439.
32. Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 1998; 17: 2215-2223.
33. Gdynia G, Grund K, Eckert A, Bock BC, Funke B, Macher-Goeppinger S et al. Basal caspase activity promotes migration and invasiveness in glioblastoma cells. Mol Cancer Res 2007; 5: 1232-1240.
34. Johnson DR, O'Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 2011; 107: 359-364.
35. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAP-targeted therapies for cancer. Oncogene 2008; 27: 6252-6275.
36. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002; 8: 808-815.
37. Vellanki SH, Grabrucker A, Liebau S, Proepper C, Eramo A, Braun V et al. Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma. Neoplasia 2009; 11: 743-752.
38. Wang S, Yan-Neale Y, Cai R, Alimov I, Cohen D. Activation of mitochondrial pathway is crucial for tumor selective induction of apoptosis by LAQ824. Cell Cycle 2006; 5: 1662-1668.
39. Kogel D, Fulda S, Mittelbronn M. Therapeutic exploitation of apoptosis and autophagy for glioblastoma. Anticancer Agents Med Chem 2010; 10: 438-449.
40. Eisele G, Weller M. Targeting apoptosis pathways in glioblastoma. Cancer Lett 2011; 332: 335-345.
41. O'Connor CL, Anguissola S, Huber HJ, Dussmann H, Prehn JH, Rehm M. Intracellular signaling dynamics during apoptosis execution in the presence or absence of X-linked-inhibitor-of-apoptosis-protein. Biochim Biophys Acta 2008; 1783: 1903-1913.
42. Mittelbronn M, Platten M, Zeiner P, Dombrowski Y, Frank B, Zachskorn C et al. Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression. Acta Neuropathol 2011; 122: 353-365.
43. Yin D, Zhou H, Kumagai T, Liu G, Ong JM, Black KL et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 2005; 24: 344-354.